246 related articles for article (PubMed ID: 15918575)
1. [A trial of biweekly paclitaxel administration in consideration of QOL for advanced or recurrent gynecologic cancer].
Fushiki H; Yoshimoto H; Ikoma T; Ota S
Gan To Kagaku Ryoho; 2005 May; 32(5):691-3. PubMed ID: 15918575
[TBL] [Abstract][Full Text] [Related]
2. [Practical use of taxol-based chemotherapy for poor compliance gynecologic cancers in Japanese woman].
Mitsui M; Takashi K; Imai K
Gan To Kagaku Ryoho; 2003 Mar; 30(3):383-9. PubMed ID: 12669398
[TBL] [Abstract][Full Text] [Related]
3. [Patient compliance and the quality of life are well maintained in weekly paclitaxel and carboplatin therapy for advanced gynecologic cancers in Japanese women].
Kurihara M; Sakamoto H; Ohta Y; Takami T; Takami M; Nakayama Y; Murata H; Ohtani K; Masaoka N; Yamamoto T; Satoh K
Gan To Kagaku Ryoho; 2001 Jan; 28(1):55-61. PubMed ID: 11201381
[TBL] [Abstract][Full Text] [Related]
4. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma].
Fujii K; Takano M; Okamoto S; Sasaki N; Kita T; Kikuchi Y
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2141-4. PubMed ID: 15628759
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial.
Kim YH; Yamaguchi K; Bang YJ; Takiuchi H; Kang WK; Sato A; Kang YK; Sakamoto J; Abe C; Sakata Y
Jpn J Clin Oncol; 2007 Jul; 37(7):501-8. PubMed ID: 17673470
[TBL] [Abstract][Full Text] [Related]
9. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
11. [Combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer].
Hokita S; Aikou T; Ishigami S; Miyazono F; Nakajo A; Uenosono Y; Hamanoue M; Aridome K; Natsugoe S
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():95-8. PubMed ID: 16897981
[TBL] [Abstract][Full Text] [Related]
12. [A case of recurrent stomach cancer treated with 5-fluorouracil responding to weekly paclitaxel therapy].
Fukuda Y; Fujio N; Ihara T; Terakura M; Takatori H; Tsukazaki T; Koyama I; Tsukazaki Y; Osugi H
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1419-22. PubMed ID: 15446569
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
[TBL] [Abstract][Full Text] [Related]
14. [Consecutive low-dose cisplatin-based chemotherapy for gynecologic malignancies].
Shimizu Y
Gan To Kagaku Ryoho; 1997 Feb; 24(4):431-8. PubMed ID: 9063480
[TBL] [Abstract][Full Text] [Related]
15. [Weekly paclitaxel infusion in patients with recurrent ovarian cancer--a pilot study].
Kawagoe H; Kawata T; Nishio S; Shimomura T; Fujiyoshi K; Ishimatsu J; Tsunawaki A
Gan To Kagaku Ryoho; 2003 Jan; 30(1):151-4. PubMed ID: 12557722
[TBL] [Abstract][Full Text] [Related]
16. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
Stathopoulos GP; Malamos NA; Aravantinos G; Rigatos S; Christodoulou Ch; Stathopoulos J; Skarlos D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):123-8. PubMed ID: 17111119
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of weekly paclitaxel administration for patients with relapsed cervical cancer after heavy medication.
Terauchi F; Nagashima T; Kobayashi Y; Yamamoto Y; Moritake T; Seiki T; Ogura H
Gan To Kagaku Ryoho; 2005 May; 32(5):641-4. PubMed ID: 15918564
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
19. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
20. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ;
J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
